Volume 23, Number 1—January 2017
CME ACTIVITY - Research
Analysis of Anthrax Immune Globulin Intravenous with Antimicrobial Treatment in Injection Drug Users, Scotland, 2009–2010
Table 5
Microbiology data and the time to confirmatory anthrax diagnosis for recipients and nonrecipients of AIG-IV, Scotland, UK, 2009–2010*
Laboratory test | AIG-IV nonrecipient | AIG-IV recipient | p value |
---|---|---|---|
Blood culture | 32 (8/25) | 71.4 (10/14) | 0.02 |
Wound culture | 46.2 (6/13) | 33.3 (3/9) | 0.67 |
Tissue culture | 54.6 (6/11) | 70 (7/10) | 0.66 |
Blood PCR | 29.4 (5/17) | 80 (8/10) | 0.02 |
Blood protective antigen antibody | 81.3 (13/16) | 66.7 (4/6) | 0.59 |
Blood lethal factor antibody | 62.5 (10/16) | 57.1 (4/7) | 1.00 |
Days to diagnosis, median (IQR) | 3.5 (2.0–30.5), n = 28 | 2.0 (1.0–3.0), n = 13 | 0.006 |
*Values are % patients (no. patients with the finding/no. patients for whom data were available) except as indicated. n values indicate no. patients for whom data were available. Bold indicates significant differences between AIG-IV recipients and nonrecipients. AIG-IV, anthrax immune globulin intravenous; IQR, interquartile range.
1These authors contributed equally to this article.